Shots:
- Kumquat to receive an ~ $70M in upfront and an equity investment in addition to ~$2B in milestone based on the achievement of definite milestones along with royalties on sales of commercialized products resulting from the collaboration
- Following the agreement, Lilly gets the option to co-commercialize in China while Kumquat has the option to co-develop and co-commercialize in the US
- Kumquat holds the development and commercialization rights in Greater China for each drug candidate that Lilly selects while Lilly has the option to select a definite number of drug candidates for further development and commercialization globally Ex- Greater China
Click here to read full press release/ article | Ref: Eli Lilly | Image: Kumquat
The post Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses first appeared on PharmaShots.
